LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Stock List・Becton Dickinson and Co

Becton Dickinson and Co

Closed

SectorHealthcare

147.18 -0.67

Buy Sell

Overview

Share price change

24h

Current

Min

146.09

Max

149.03

Key metrics
By Trading Economics
Income	-692M -310M
Sales	-538M 4.7B
P/E Sector Avg	25.764 50.102
EPS	2.9
Dividend yield	2.86
Profit margin	-6.576
Employees	60,000
EBITDA	-1B 189M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+22.9% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	2.86% 2.33%
Next Earnings	6 Aug 2026
Next Dividend date	30 Jun 2026
Next Ex Dividend date	9 Jun 2026

Market Stats
By TradingEconomics
Market Cap	-942M 41B
Previous open	147.85
Previous close	147.18

News Sentiment

By Acuity

21%

79%

45 / 344 Healthcare

Becton Dickinson and Co Chart

Past performance is not a reliable indicator of future results.

Related News

7 Aug 2025, 11:19 UTC

Earnings

Becton Dickinson Boosts Outlook as 3Q Results Beat Estimates

14 Jul 2025, 14:26 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

14 Jul 2025, 11:08 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

14 Jul 2025, 10:37 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

7 Aug 2025, 10:32 UTC

Earnings

Becton Dickinson Expects to Complete Remaining $250M of $1B Share-Buyback Commitment by End FY25 >BDX

7 Aug 2025, 10:31 UTC

Earnings

Becton Dickinson Backs FY25 View of Rev $21.8B-$21.9B >BDX

7 Aug 2025, 10:31 UTC

Earnings

Becton Dickinson Had Seen FY25 Adjusted EPS $14.06-$14.34 >BDX

7 Aug 2025, 10:30 UTC

Earnings

Becton Dickinson Raises FY25 View To Adj EPS $14.30-Adj EPS $14.45 >BDX

7 Aug 2025, 10:30 UTC

Earnings

Becton Dickinson 3Q Adj EPS $3.68 >BDX

7 Aug 2025, 10:30 UTC

Earnings

Becton Dickinson 3Q Net $574M >BDX

7 Aug 2025, 10:30 UTC

Earnings

Becton Dickinson 3Q Rev $5.51B >BDX

7 Aug 2025, 10:30 UTC

Earnings

Becton Dickinson 3Q EPS $2.00 >BDX

15 Jul 2025, 18:32 UTC

Acquisitions, Mergers, Takeovers

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 Jul 2025, 18:31 UTC

Acquisitions, Mergers, Takeovers

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

14 Jul 2025, 16:12 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14 Jul 2025, 15:06 UTC

Acquisitions, Mergers, Takeovers

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

14 Jul 2025, 14:11 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

14 Jul 2025, 10:53 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

14 Jul 2025, 10:22 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

14 Jul 2025, 10:22 UTC

Acquisitions, Mergers, Takeovers

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

14 Jul 2025, 10:22 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

14 Jul 2025, 10:21 UTC

Acquisitions, Mergers, Takeovers

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

14 Jul 2025, 10:20 UTC

Acquisitions, Mergers, Takeovers

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

14 Jul 2025, 10:19 UTC

Acquisitions, Mergers, Takeovers

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

14 Jul 2025, 10:19 UTC

Acquisitions, Mergers, Takeovers

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

14 Jul 2025, 10:18 UTC

Acquisitions, Mergers, Takeovers

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

14 Jul 2025, 10:18 UTC

Acquisitions, Mergers, Takeovers

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

14 Jul 2025, 10:17 UTC

Acquisitions, Mergers, Takeovers

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

14 Jul 2025, 10:16 UTC

Acquisitions, Mergers, Takeovers

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

14 Jul 2025, 10:16 UTC

Acquisitions, Mergers, Takeovers

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

Peer Comparison

Price change

Becton Dickinson and Co Forecast

Price Target

By TipRanks

22.9% upside

12 Months Forecast

Average 182.4 USD 22.9%

High 221 USD

Low 161 USD

Based on 10 Wall Street analysts offering 12 month price targets forBecton Dickinson and Co - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Becton Dickinson and Co - Dist in the past 3 months.

Sentiment

By Acuity

45 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.